Last reviewed · How we verify
NCT03819972: PROCAL
The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations
NA trial testing Dose response of Capolac® in GLP-1 Concentration in 18 participants. Completed in 31 March 2021.
31 March 2020
Quick facts
| Lead sponsor | University of Bath |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 18 |
| Start date | 2 February 2019 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 March 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Dose response of Capolac®
Conditions studied
- GLP-1 Concentration — all drugs for GLP-1 Concentration →
Sponsor
University of Bath
Who can join
Adults 18 to 65, any sex, with GLP-1 Concentration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hormones that are produced by our stomach and intestines play a role in regulating our appetite and health. One of the most important hormones is called GLP-1. The food we eat influences the release of this hormone and evidence suggests that protein and calcium are key nutrients that stimulate the secretion of GLP-1. We want to know if there is a dose related response by increasing the amount of calcium ingested with a constant amount of protein on the release of this hormone. We hypothesise that with increasing calcium dose we will see an increase in GLP-1 concentrations in a curvilinear pattern. This may have benefits for prescribing an optimal dose of calcium for weight maintenance and health.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium.
Watkins JD, Smith HA, Hengist A, Brunsgaard LH, et al · · 2021 · cited 4× · PMID 34369333 · DOI 10.1017/s000711452100297x -
Are there sex differences in the variability of fasting metabolism?
Bradshaw L, Buniam J, Betts JA, Gonzalez JT. · · 2024 · cited 2× · PMID 38634507 · DOI 10.1152/japplphysiol.00053.2024
Verify or expand the search:
- PubMed search for NCT03819972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Bath trials
Trials by the same sponsor.
- NCT07360249 — Glucose-fructose Ratio Pilot · NA · recruiting
- NCT06967077 — Exploring the Feasibility and Acceptability of Virtual Reality Exercise for Pain Management, Fear of Movement, Mobility, · NA · not yet recruiting
- NCT07472244 — Does the Development of the Repeated Bout Effect Depend on Oxidative Stress and Inflammation? · NA · recruiting
- NCT07099911 — Neuromuscular Electrical Stimulation and Glucose Control in Spinal Cord Injury · NA · recruiting
- NCT07027553 — Remote Exercise to Improve Physical Activity Levels and Markers of Heart Health in Cystic Fibrosis (RHH-CF) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03819972 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bath
- Last refreshed: 28 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03819972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing